CHEK1 and pancreatic neoplasm: Both studies, one performed in TNBC and the other in pancreatic tumour models, demonstrated an increase in radiosensitivity following pre-treatment with the Chk1 inhibitors PF-00477736 or LY2606368 [14, 32], although the development of PF-00477736 has since been discontinued [33, 34].